LINC01170: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

Target Name: LINC01170

NCBI ID: G103724389

LINC01170

Other Name(s): long intergenic non-protein coding RNA 1170 | Long intergenic non-protein coding RNA 1170

LINC01170: A Long Intergenic Non-Protein-Coding RNA and Its Potential as a Drug Target

LINC01170 is a long intergenic non-protein-coding RNA (lncRNA) that has been identified in various studies as having important functional roles in various organisms, including humans. This RNA has been shown to play a significant role in the regulation of gene expression, DNA replication, and chromatin remodeling, among other functions. Its unique properties and involvement in various biological processes have led to its potential as a drug target or biomarker.

Properties of LINC01170

LINC01170 is a long non-coding RNA molecule that contains approximately 1,800 exons and 11,000 base pairs. It is expressed in various tissues and cells of the body and has been shown to play a role in regulating gene expression in various organisms, including humans. LINC01170 is characterized by the presence of a stem-loop structure, which is a common feature of many non-coding RNAs, and is composed of a series of alternating between G- and A-rich loops.

Functional Analysis of LINC01170

LINC01170 has been shown to have various functional roles in various biological processes. One of its well-documented functions is its role in regulating gene expression. LINC01170 has been shown to interact with various transcription factors, including RNA polymerase II (RNA-P2), to regulate gene expression.

In addition to its role in gene expression, LINC01170 has also been shown to play a significant role in DNA replication. LINC01170 has been shown to be involved in the regulation of DNA replication by the enzyme responsible for the initiation of the replication process, called DNA polymerase.

Another function of LINC01170 is its role in chromatin remodeling. LINC01170 has been shown to play a role in the regulation of chromatin remodeling by the enzyme responsible for the removal of histone modifications, called histone-remodeling enzyme.

Potential Therapeutic Applications

The unique properties of LINC01170, including its long non-coding RNA molecule and its involvement in various functional roles in various biological processes, make it an attractive candidate for therapeutic applications. Several studies have investigated the potential therapeutic applications of LINC01170, including its potential as a drug target or biomarker.

One potential therapeutic application of LINC01170 is its use as a drug target for the treatment of various diseases, including cancer. LINC01170 has been shown to play a role in the regulation of cell growth and has been shown to be involved in the development of various types of cancer.

Another potential therapeutic application of LINC01170 is its use as a biomarker for various diseases, including cancer. LINC01170 has been shown to be expressed in various types of cancer and has been shown to play a role in the regulation of various biological processes that are associated with the development and progression of cancer.

Conclusion

LINC01170 is a long intergenic non-protein-coding RNA molecule that has been identified in various studies as having important functional roles in various organisms, including humans. Its unique properties and involvement in various biological processes have led to its potential as a drug target or biomarker. Further research is needed to fully understand the functional roles of LINC01170 in various biological processes and to explore its potential as a therapeutic

Protein Name: Long Intergenic Non-protein Coding RNA 1170

The "LINC01170 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01170 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets